Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 5:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 287 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Erythromycin ethyl succinate Clear all
Completed Phase 3 Interventional Results available

Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease

NCT03009396
View directory record Official record
Conditions
Crohn Disease
Interventions
RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years to 76 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
San Carlos, California • Marietta, Georgia • Topeka, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Sep 21, 2026, 5:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Electrophysiological Effects of Potential QT Prolonging Drugs

NCT05716854
View directory record Official record
Conditions
Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics
Interventions
Clarithromycin, Pimozide, Placebo (Part 1), Moxifloxacin, Cobicistat, Moxifloxacin and Cobicistat, Placebo (Part 2)
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 21, 2026, 5:53 PM EDT
Completed Phase 2 Interventional Results available

Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants

NCT01778634
View directory record Official record
Conditions
Ureaplasma Infections
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
2 Hours to 72 Hours
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • Newark, Delaware • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2020 · Synced Sep 21, 2026, 5:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants

NCT05965570
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Brensocatib, Clarithromycin
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2023 · Synced Sep 21, 2026, 5:53 PM EDT
Completed Phase 2 Interventional Results available

Prospective Pilot Clinical Trial of Azithromycin Treatment In Respiratory Syncytial Virus (RSV)- Induced Respiratory Failure In Children

NCT02707523
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Azithromycin 10 mg, Azithromycin 20mg, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Up to 16 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Sep 21, 2026, 5:53 PM EDT
Completed Phase 3 Interventional

Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease

NCT00002827
View directory record Official record
Conditions
Cardiac Toxicity, Lymphoma
Interventions
bleomycin sulfate, filgrastim, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2008
U.S. locations
36
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2013 · Synced Sep 21, 2026, 5:53 PM EDT
Recruiting Phase 4 Interventional

Extended Azithromycin Treatment in Prelabor Rupture of Membranes

NCT07669207
View directory record Official record
Conditions
Preterm Prelabor Rupture of Membranes, PPROM
Interventions
Azithromycin (Azithro), Standard Azithromycin Dosing
Drug
Lead sponsor
Alexa Henderson
Other
Eligibility
Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 21, 2026, 5:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single Dose Pharmacokinetics of Deflazacort

NCT02286635
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Deflazacort and rifampin, Deflazacort and Clarithromycin
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 21, 2026, 5:53 PM EDT
Completed No phase listed Observational

Fluoroquinolone Associated Disability

NCT03535558
View directory record Official record
Conditions
Bronchitis, Sinusitis, Urinary Tract Infections
Interventions
Fluoroquinolone (FQ), Azithromycin (AZ), Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
239,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Sep 21, 2026, 5:53 PM EDT
Completed Phase 1 Interventional

A Study of Azithromycin in HIV-Infected Patients

NCT00002344
View directory record Official record
Conditions
Bacterial Infections, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 21, 2026, 5:53 PM EDT
Terminated Not applicable Interventional

Treatment of Chronic Cryptosporidiosis in AIDS Patients

NCT00001128
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Interleukin-12, Paromomycin sulfate, Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Sep 21, 2026, 5:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Clarithromycin 500 mg Tablets Under Non-Fasting Conditions

NCT00836706
View directory record Official record
Conditions
Healthy
Interventions
clarithromycin, BIAXIN®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
East Grand Forks, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 21, 2026, 5:53 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Infant Mortality Reduction by the Mass Administration of Azithromycin

NCT04716712
View directory record Official record
Conditions
Child Mortality
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Month to 11 Months
Enrollment
694,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Sep 21, 2026, 5:53 PM EDT
Completed Phase 4 Interventional

Azithromycin in the Treatment of M. Avium Complex Lung Disease

NCT00599079
View directory record Official record
Conditions
Mycobacterium Avium Complex Lung Disease
Interventions
Azithromycin
Drug
Lead sponsor
The University of Texas Health Science Center at Tyler
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2017
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Sep 21, 2026, 5:53 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia

NCT02605122
View directory record Official record
Conditions
Community-acquired Bacterial Pneumonia
Interventions
Solithromycin, Standard of Care
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
2 Months to 17 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Sep 21, 2026, 5:53 PM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of Clarithromycin Plus Ethambutol Used With or Without Clofazimine in the Treatment of MAC in Patients With AIDS

NCT00002331
View directory record Official record
Conditions
Mycobacterium Avium-intracellular Infection, HIV Infections
Interventions
Ethambutol hydrochloride, Clarithromycin, Clofazimine
Drug
Lead sponsor
Abbott
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1995
U.S. locations
17
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 21, 2026, 5:53 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Effect of Concomitant Administration of Erythromycin and Diltiazem on CYP3A Activity in Healthy Volunteers

NCT00318201
View directory record Official record
Conditions
Healthy
Interventions
Erythromycin, Diltiazem
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 50 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 5, 2012 · Synced Sep 21, 2026, 5:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men

NCT04714554
View directory record Official record
Conditions
Healthy
Interventions
Relugolix/E2/NETA FDC, Relugolix, Erythromycin
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Sep 21, 2026, 5:53 PM EDT
Completed Phase 4 Interventional Results available

Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa

NCT00431964
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
azithromycin 250 mg tablets, placebo tablets
Drug
Lead sponsor
CF Therapeutics Development Network Coordinating Center
Network
Eligibility
6 Years to 18 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
31
States / cities
Phoenix, Arizona • Hartford, Connecticut • Atlanta, Georgia + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Sep 21, 2026, 5:53 PM EDT
Active, not recruiting Phase 3 Interventional

Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes

NCT06273891
View directory record Official record
Conditions
Premature Rupture of Membrane
Interventions
Erythromycin, Azithromycin
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Falls Church, Virginia • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 21, 2026, 5:53 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term

NCT03801252
View directory record Official record
Conditions
Obesity, Induction of Labor Affected Fetus / Newborn
Interventions
Cefazolin, Placebo, Azithromycin
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 21, 2026, 5:53 PM EDT
Completed Not applicable Interventional Results available

Study of Anesthesia Techniques to Reduce Nausea and Vomiting After Jaw Corrective Surgery

NCT01592708
View directory record Official record
Conditions
Post-operative Nausea, Post-operative Vomiting, Nausea Persistent
Interventions
Antiemetic anesthesia protocol
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Sep 21, 2026, 5:53 PM EDT
Recruiting No phase listed Observational

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

NCT03511118
View directory record Official record
Conditions
Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Interventions
Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
20
States / cities
La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 21, 2026, 5:53 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404
View directory record Official record
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 21, 2026, 5:53 PM EDT